-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
On March 31, Corning Jereh announced that the first phase III clinical study of the company's PD-L1/CTLA-4 dual antibody KN046 (study number: ENREACH-LUNG-01) successfully completed the first interim analysis and reached the preset endpoint
KN046 is the world's first PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.
ENREACH-LUNG-01 is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study of KN046 in combination with platinum-based chemotherapy in patients with advanced unresectable or metastatic squamous non-small cell lung cancer.
First interim analysis by the Independent Data Monitoring Committee (iDMC), KN046 plus platinum-based chemotherapy versus placebo plus Platinum chemotherapy resulted in a significant and clinically meaningful prolongation of progression-free survival (PFS) in patients with advanced squamous non-small cell lung cancer, meeting pre-specified superiority criteria
KN046 has carried out nearly 20 clinical trials at different stages covering more than 10 types of tumors, including non-small cell lung cancer, thymic cancer, pancreatic cancer, liver cancer, esophageal squamous cell carcinoma, and triple-negative breast cancer in Australia, the United States and China.
